Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naohiro Oda

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|April 25, 2017
Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary diseaseNaohiro Oda, Nobuaki Miyahara, Hirohisa Ichikawa, et al.
Respiratory Research|January 25, 2017
Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthmaUtako Fujii, Nobuaki Miyahara, Akihiko Taniguchi, et al.
Journal of Cancer Research and Clinical Oncology|March 29, 2021
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitorsNaofumi Hara, Eiki Ichihara, Daijiro Harada, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2019
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancerEiki Ichihara, Daijiro Harada, Koji Inoue, et al.
Cancer Immunology, Immunotherapy : CII|July 11, 2020
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitorsEiki Ichihara, Daijiro Harada, Koji Inoue, et al.
Japanese Journal of Clinical Oncology|October 13, 2020
Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancerShinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2021
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expressionNobuaki Ochi, Eiki Ichihara, Nagio Takigawa, et al.
American Journal of Respiratory Cell and Molecular Biology|September 19, 2022
Neuropeptide Y Antagonizes Development of Pulmonary Fibrosis through IL-1β InhibitionJunko Itano, Akihiko Taniguchi, Satoru Senoo, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2018
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403Naohiro Oda, Kastuyuki Hotta, Kiichiro Ninomiya, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|September 15, 2021
Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosisSatoru Senoo, Akihiko Taniguchi, Junko Itano, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
International Journal of Chronic Obstructive Pulmonary Disease|April 25, 2017
Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary diseaseNaohiro Oda, Nobuaki Miyahara, Hirohisa Ichikawa, et al.
Respiratory Research|January 25, 2017
Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthmaUtako Fujii, Nobuaki Miyahara, Akihiko Taniguchi, et al.
Journal of Cancer Research and Clinical Oncology|March 29, 2021
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitorsNaofumi Hara, Eiki Ichihara, Daijiro Harada, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2019
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancerEiki Ichihara, Daijiro Harada, Koji Inoue, et al.
Cancer Immunology, Immunotherapy : CII|July 11, 2020
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitorsEiki Ichihara, Daijiro Harada, Koji Inoue, et al.
Japanese Journal of Clinical Oncology|October 13, 2020
Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancerShinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2021
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expressionNobuaki Ochi, Eiki Ichihara, Nagio Takigawa, et al.
American Journal of Respiratory Cell and Molecular Biology|September 19, 2022
Neuropeptide Y Antagonizes Development of Pulmonary Fibrosis through IL-1β InhibitionJunko Itano, Akihiko Taniguchi, Satoru Senoo, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2018
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403Naohiro Oda, Kastuyuki Hotta, Kiichiro Ninomiya, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|September 15, 2021
Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosisSatoru Senoo, Akihiko Taniguchi, Junko Itano, et al.
Pageof 7